Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371993 | 0.76 | CHRNB2 (0.45) | SIGMAR1OPRM1HTR2CHTR2BHTR2A | |
| SCHEMBL19199705 | 0.76 | CHRNB2 (0.45) | SIGMAR1OPRM1HTR2CHTR2BHTR2A | |
| SCHEMBL12371996 | 0.76 | DRD2 (0.39) | SIGMAR1OPRL1OPRM1SLC6A2SLC6A3 | |
| SCHEMBL12372000 | 0.73 | SIGMAR1 (0.47) | SIGMAR1SLC6A2SLC6A3SLC6A4HTR2C | |
| SCHEMBL21079136 | 0.72 | ACHE (0.48) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12371998 | 0.70 | SIGMAR1 (0.44) | SIGMAR1SLC6A2SLC6A3SLC6A4HTR2C | |
| SCHEMBL20245626 | 0.66 | OPRM1 (0.42) | SIGMAR1OPRM1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL18099210 | 0.65 | SIGMAR1 (0.59) | SIGMAR1SLC6A4 | |
| SCHEMBL8207826 | 0.64 | HTR2C (0.50) | SIGMAR1KCNH2OPRM1SLC6A2SLC6A3 | |
| SCHEMBL3090108 | 0.64 | MAPT (0.50) | SIGMAR1SLC6A2SLC6A3SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859580-B2 | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | HSD3B1, CYP11B1, HSD11B1 | SIGMAR1 287/4885OPRL1 280/4885KCNH2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.